Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation

International Journal of Oncology

Volumn 47, Issue 6, 2015, Pages 2073-2081

  Mawatari, Toshiki ^a   Ninomiya, Itasu ^a   Inokuchi, Masafumi ^b   Harada, Shinichi ^b   Hayashi, Hironori ^a   Oyama, Katsunobu ^a   Makino, Isamu ^a   Nakagawara, Hisatoshi ^a   Miyashita, Tomoharu ^a   Tajima, Hidehiro ^a   Takamura, Hiroyuki ^a   Fushida, Sachio ^a   Ohta, Tetsuo ^a  

^a Department of Oncology   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Breast cancer; HDAC inhibitor; HER2; Hsp70; Hsp90; Valproic acid

Indexed keywords

ALPHA TUBULIN; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTONE H3; VALPROIC ACID; ERBB2 PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN EXPRESSION; SKBR3 CELL LINE; TUNEL ASSAY; UPREGULATION; WESTERN BLOTTING; ACETYLATION; BREAST TUMOR; CELL CYCLE CHECKPOINT; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACETYLATION; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; RECEPTOR, ERBB-2; VALPROIC ACID;

EID: 84982746744     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3213     Document Type: Article

References (39)

1. Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796-1804, 2012.
2. Fang JY and Lu YY: Effects of histone acetylation and DNA methylation on p21 (WAF1) regulation. World J Gastroenterol 8:400-405, 2002.
3. Jenuwein T and Allis CD: Translating the histone code. Science 293:1074-1080, 2001.
4. Davie JR and Moniwa M: Control of chromatin remodeling. Crit Rev Eukaryot Gene Expr 10:303-325, 2000.
5. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784, 2006.
6. Monneret C: Histone deacetylase inhibitors. Eur J Med Chem 40:1-13, 2005.
7. Sami S, Höti N, Xu HM, Shen Z and Huang X: Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem 144:357-362, 2008.
8. Krämer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, Brill B, Groner B, Bach I, Heinzel T, et al: The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22:3411-3420, 2003.
9. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20:6969-6978, 2001.
10. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K and Denk H: Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5:2203-2210, 2006.
11. Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, Bianucci F, Guerra F, Pession A and Ferreri AM: p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 13:1139-1144, 2005.
12. Takai N, Narahara H, Takai N and Narahara H: Human endometrial and ovarian cancer cells: Histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem 14:2548-2553, 2007.
13. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA and Schrump DS: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94:504-513, 2002.
14. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T and Bates SE: Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 1:937-941, 2002.
15. Catalano MG, Poli R, Pugliese M, Fortunati N and Boccuzzi G: Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 14:839-845, 2007.
16. Fortunati N, Bertino S, Costantino L, Bosco O, Vercellinatto I, Catalano MG and Boccuzzi G: Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett 259:156-164, 2008.
17. Travaglini L, Vian L, Billi M, Grignani F and Nervi C: Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol 41:225-234, 2009.
18. Zhang L, Wang G, Wang L, Song C, Leng Y, Wang X and Kang J: VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin. Mol Cell Biochem 361:39-45, 2012.
19. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, et al: Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63:5126-5135, 2003.
20. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF and Yao TP: HDAC6 is a microtubuleassociated deacetylase. Nature 417:455-458, 2002.
21. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, et al: Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280:26729-26734, 2005.
22. Bali P, Pranpat M, Swaby R, et al: Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 11:6382-6389, 2005.
23. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB and Yao TP: HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18:601-607, 2005.
24. Powers MV, Clarke PA and Workman P: Death by chaperone: HSP90, HSP70 or both? Cell Cycle 8:518-526, 2009.
25. Pratt WB and Toft DO: Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228:111-133, 2003.
26. Boyault C, Zhang Y, Fritah S, Caron C, Gilquin B, Kwon SH, Garrido C, Yao TP, Vourc'h C, Matthias P, et al: HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 21:2172-2181, 2007.
27. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S and Matthias P: HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 22:1168-1179, 2003.
28. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, et al: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916-4921, 2002.
29. Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8(Suppl):S55-S61, 2002.
30. Giacinti L, Giacinti C, Gabellini C, Rizzuto E, Lopez M and Giordano A: Scriptaid effects on breast cancer cell lines. J Cell Physiol 227:3426-3433, 2012.
31. Olsen CM, Meussen-Elholm ET, Røste LS and Taubøll E: Antiepileptic drugs inhibit cell growth in the human breast cancer cell line MCF7. Mol Cell Endocrinol 213:173-179, 2004.
32. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, et al: Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 6:2, 2006.
33. Hodges-Gallagher L, Valentine CD, Bader SE and Kushner PJ: Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 105:297-309, 2007.
34. Li GF, Qian TL, Li GS, Yang CX, Qin M, Huang J, Sun M and Han YQ: Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression. Genet Mol Res 11:77-86, 2012.
35. Huang X, Gao L, Wang S, Lee CK, Ordentlich P and Liu B: HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res 69:8403-8411, 2009.
36. Wang Y, Wang SY, Zhang XH, Zhao M, Hou CM, Xu YJ, Du ZY and Yu XD: FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem Biophys Res Commun 356:998-1003, 2007.
37. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P and Bhalla K: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971-984, 2003.
38. Scott GK, Marden C, Xu F, Kirk L and Benz CC: Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol Cancer Ther 1:385-392, 2002.
39. Meng Q, Chen X, Sun L, Zhao C, Sui G and Cai L: Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90. Mol Cell Biochem 348:165-171, 2011.